The DOI matches its Crossref record.
A method to determine the ability of drugs to diffuse through the blood-brain barrier.
Open accessAbstract
A method has been devised for predicting the ability of drugs to cross the blood-brain barrier. The criteria depend on the amphiphilic properties of a drug as reflected in its surface activity. The assessment was made with various drugs that either penetrate or do not penetrate the blood-brain barrier. The surface activity of these drugs was quantified by their Gibbs adsorption isotherms in terms of three parameters: (i) the onset of surface activity, (ii) the critical micelle concentration, and (iii) the surface area requirement of the drug at the air/water interface. A calibration diagram is proposed in which the critical micelle concentration is plotted against the concentration required for the onset of surface activity. Three different regions are easily distinguished in this diagram: a region of very hydrophobic drugs which fail to enter the central nervous system because they remain adsorbed to the membrane, a central area of less hydrophobic drugs which can cross the blood-brain barrier, and a region of relatively hydrophilic drugs which do not cross the blood-brain barrier unless applied at high concentrations. This diagram can be used to predict reliably the central nervous system permeability of an unknown compound from a simple measurement of its Gibbs adsorption isotherm.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Artursson, P., Palm, K., & Luthman, K. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00128-9 · Cited by 1,543
Schinkel, A. H., Wagenaar, E., Mol, C. A., & van Deemter, L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118699 · Cited by 1,264
High throughput artificial membrane permeability assay for blood–brain barrier
Di, L., Kerns, E. H., Fan, K., McConnell, O. J., & Carter, G. T. (2003) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(03)00012-6 · Cited by 1,195
P-Glycoprotein, a gatekeeper in the blood–brain barrier
Schinkel, A. H. (1999) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00085-4 · Cited by 960
Schreier, S., Malheiros, S. V. P., & de Paula, E. (2000) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0304-4157(00)00012-5 · Cited by 727
van de Waterbeemd, H., Camenisch, G., Folkers, G., Chretien, J. R., & Raevsky, O. A. (1998) · Journal of Drug Targeting · doi:10.3109/10611869808997889 · Cited by 587
Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles☆
WONG, H., BENDAYAN, R., RAUTH, A., LI, Y., & WU, X. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.04.008 · Cited by 578
Drug Delivery Systems, CNS Protection, and the Blood Brain Barrier
Upadhyay, R. K. (2014) · BioMed Research International · doi:10.1155/2014/869269 · Cited by 528
Wohnsland, F., & Faller, B. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm001020e · Cited by 492
In silico prediction of blood–brain barrier permeation
Clark, D. E. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02827-7 · Cited by 483
Transporting therapeutics across the blood-brain barrier
Abbott, N. J., & Romero, I. A. (1996) · Molecular Medicine Today · doi:10.1016/1357-4310(96)88720-x · Cited by 447
Moosmann, B., & Behl, C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.8867 · Cited by 411
Blood-Brain Barrier Permeation: Molecular Parameters Governing Passive Diffusion
Fischer, H., Gottschlich, R., & Seelig, A. (1998) · Journal of Membrane Biology · doi:10.1007/s002329900434 · Cited by 371
Self-citationCaco-2 monolayers in experimental and theoretical predictions of drug transport
Artursson, P., Palm, K., & Luthman, K. (1996) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00415-2 · Cited by 326
Designing Libraries with CNS Activity
Ajay, Bemis, G. W., & Murcko, M. A. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm990017w · Cited by 316
Phenothiazine: the seven lives of pharmacology's first lead structure
Ohlow, M. J., & Moosmann, B. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.01.001 · Cited by 280
Caco-2 monolayers in experimental and theoretical predictions of drug transport
Artursson, P., Palm, K., & Luthman, K. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.005 · Cited by 279
Transport of small molecules through the blood-brain barrier: biology and methodology
Pardridge, W. M. (1995) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00003-p · Cited by 279
Structure–activity relationship of P-glycoprotein substrates and modifiers
Seelig, A., & Landwojtowicz, E. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00177-9 · Cited by 275
Self-citationHalogenation of Drugs Enhances Membrane Binding and Permeation
Gerebtzoff, G., Li‐Blatter, X., Fischer, H., Frentzel, A., & Seelig, A. (2004) · ChemBioChem · doi:10.1002/cbic.200400017 · Cited by 271
Self-citationEarly pharmaceutical profiling to predict oral drug absorption: Current status and unmet needs
Bergström, C. A. S., Holm, R., Jørgensen, S. A., Andersson, S. B. E., Artursson, P., Beato, S., Borde, A., Box, K., Brewster, M., Dressman, J., et al. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.10.015 · Cited by 257
van de Haar, H. J., Jansen, J. F. A., Jeukens, C. R. L. P. N., Burgmans, S., van Buchem, M. A., Muller, M., Hofman, P. A. M., Verhey, F. R. J., van Osch, M. J. P., & Backes, W. H. (2017) · Medical Physics · doi:10.1002/mp.12328 · Cited by 85
“The most common contrast agents in MRI are gadolinium-based compounds, which almost completely remain intravascular in a healthy brain due to the BBB.5,6 The BBB is a collection of anatomical elements in the wall of brain capillaries.”
Background
Metadata
- Authors
- Seelig, A., Gottschlich, R., & Devant, R. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1994-01-04
- Volume
- 91
- Issue
- 1
- Pages
- 68-72
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2030950703
- Cited by
- 197
- References
- 0
- FWCI
- 4.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.